A Study of KM501 in Patients With Solid Tumors

NCT05804864 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: KM501

Sponsor

Xuanzhu Biopharmaceutical Co., Ltd.